About BARDA DRIVe

The Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation, and Ventures (DRIVe) is a bold new approach to achieving once-unthinkable solutions to health security challenges – through the power of collaboration and innovation. DRIVe’s mission is to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats.

DRIVe is forming unique public private partnerships. DRIVe will leverage new authorities given to BARDA under the 21st Century Cures Act to stimulate innovation through both non-dilutive funding and dilutive funding. In addition, through our DRIVe Accelerator Network, we will have teams forward deployed throughout the USA to identify promising solutions wherever innovation is happening.

Accelerator 

The Center for Biotechnology at Stony Brook University has been selected as one of eight accelerators in the nation by the U.S. Department of Health and Human Services (HHS) to drive innovation in lifesaving medical technologies that solve challenging problems spanning modern health security threats and daily medical care.

Accelerators will scout out innovative technologies and products that can be developed to solve healthcare challenges that extend beyond traditional vaccine and drug development. To assist startups and other businesses in developing their technologies and products, accelerators will connect them with essential product development and business support services. This support could position innovative technologies and products for follow-on investment from the public or private sectors.

Portfolio Companies 

To date, BARDA DRIVe has provided funding to six companies. EnLiSense, Spire and Biobeat are part of the ENACT focus area, while InnaMed, Prenosis and CytoVale are part of the Solving Sepsis focus area.

Click here to view a comprehensive overview of the companies, prepared for First Flight Venture Center and NCBiotech by NCBiotech Life Science Intelligence. (Updated 05/2019)

Current Funding Opportunities 

Medical countermeasure development efforts for 2019-nCoV: BARDA’s EZ BAA program seeks abstract submissions for select 2019-nCoV diagnostics only. Please see solicitation BAA-20-100-SOL-0002 for more information. Special Instructions for a new AOI #4 focused on diagnostics for the 2019 novel Coronavirus can be found here. Deadline for submissions is March 18, 2020, unless otherwise extended.

Learn more about the BARDA DRIVe Program here.

**The Center for Biotechnology is interested in working with potential applicants to help ensure the submission of a robust on-target proposal. If you are interested learning about how the Center for Biotechnology can help, please contact William Hanes: william.hanes@stonybrook.edu***

Media Coverage:

Forbes – June 8, 2018 “An Unlikely Biotech Investor: The Government”
Newsday – June 5, 2018 “Stony Brook center tapped for federal anti-infection program”
Innovate Long Island – June 5, 2018 “SBU Joins Elite HHS Business-Development Task Force”
Stony Brook News – July 31, 2019 “Center for Biotechnology Tapped for New Healthcare Security Innovation Program”

Have questions? Looking more information? Contact DRIVeContracting@hhs.gov